A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

India is moving closer to its goal of eliminating malaria by 2030. Between 2022 to 2025, 160 districts across the country reported zero indigenous malaria cases, according to the Union Health Ministry.

The country has also saw nearly 80% decline in malaria cases and deaths between 2015 and 2025. The number of districts with high malaria burden also went down from 155 to 33.

The latest figures were discussed at a review meeting chaired by Aradhana Patnaik, Additional Secretary and Mission Director, National Health Mission, with officials from the Ministry of Health and Family Welfare, National Centre for Vector Borne Diseases Control (NCVBDC), states and affected districts.

160 Districts Reported Zero Malaria Cases In Last 3 Years

160 districts reported zero indigenous malaria cases from 2022 to 2025. This is significant as it suggests that local transmission was successfully interrupted in these regions.

But zero reported cases does not mean the risk has vanished completely. Malaria can return when mosquitoes, infected people or favourable environmental conditions fuel transmission. To avoid this, health authorities are vigilantly continuing surveillance even in areas that have made substantial progress.

The government said the reduction in numbers reflects the positive impact of focused malaria control and elimination initiatives and strategies. According to PIB, It including surveillance, early diagnosis, treatment and control measures for vector-borne infections.

Also read: Malaria Alert in Germany: Frankfurt Airport Worker Dies After ‘Mosquito Arrives On Plane’; 5 Infected

Strategies Needed For Malaria Elimination

Patnaik stressed that India cannot rely on a one-size-fits-all approach as it moves towards elimination. He said, “Focused, area-specific strategies and strengthened surveillance are essential to accelerate India’s progress towards malaria elimination by 2030.”

The Health Ministry has identified 33 high-burden districts across nine states and Union Territories for particularly intensive action. These districts accounted for 64% of India's malaria cases and 54% of malaria deaths in 2025.

The states and UTs reviewed included Mizoram, Odisha, Tripura, Assam, Andhra Pradesh, Andaman and Nicobar Islands, Chhattisgarh, Jharkhand and Maharashtra.

Despite the overall decline, malaria deaths continue to occur, and authorities highlighted that delays in diagnosis and treatment are the primary driving factors.

The government has asked states to strengthen the “Test, Treat and Track” strategy, improve active surveillance and ensure that diagnostic tests and anti-malarial medicines remain available, particularly in remote areas.

Also read: World Mosquito Day: How Dengue Can Damage Your Kidneys

The Real Challenge For India

Malaria is transmitted through the bite of infected Anopheles mosquitoes. The parasite enters the bloodstream and can cause fever, chills, headache and body aches. In severe cases, it can affect the brain and other organs and become life-threatening.

The challenge for India now is not simply reducing cases, but preventing malaria from coming back in districts where transmission has become zero.

Patnaik stressed, “Health interventions alone cannot address several factors contributing to malaria transmission, including water-logging, source reduction and environmental management.”

The government has therefore called for greater coordination with rural and urban development departments, Panchayati Raj institutions and local communities to identify breeding sites and report suspected cases early.

Myocardial infarction (MI) is one of the most common cardiovascular disorders, with an estimated prevalence of 3.8% in individuals aged less than 60 years and 9.5% in those aged over 60 years. MI remains a leading cause of death and is a significant public health concern worldwide.

But a heart attack isn't one single disease with one single mechanism. Being able to classify the type of myocardial infarction quickly can improve diagnosis and treatment.

In view of this, four major cardiac societies—the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the American Heart Association (AHA) and the World Heart Federation (WHF)—have jointly launched the Fifth Universal Definition of Myocardial Infarction.

The Fifth Universal Definition of Myocardial Infarction replaces numerical labels with three clinically meaningful categories.

The new approach aims to help healthcare professionals make more consistent diagnoses and enable patients to understand their condition better.

The new definition also aligns with the International Classification of Diseases (ICD) coding, which captures statistics on the extent, causes and consequences of different diseases.

“People may think of an MI as a heart attack caused by a blocked coronary artery but there are many different causes of MI,” explained ESC Chair, Professor Nicholas Mills from the University of Edinburgh, UK.

“The previous universal definition used a numerical system to categorize the different types of MI but this was not always easy to apply in clinical practice, leading to inconsistencies in diagnosis and treatment. The ESC, ACC, AHA and WHF have worked together to devise an updated and simplified classification system for MI, which aims to address these limitations.”

What Does the Fifth UDMI Mean?

The Fifth Universal Definition of Myocardial Infarction updates the classification to better reflect underlying pathophysiology, align with the clinical evaluation of patients, and incorporate objective diagnostic criteria.

Notably, it could facilitate wider study of less common mechanisms of primary MI, such as spontaneous coronary artery dissection (SCAD), a condition occurring predominantly in women that is currently underdiagnosed.

What Are the 3 New Heart Attack Categories?

The new system considers the underlying cause of MI and aligns the diagnosis with established approaches to clinical evaluation. It recognises that MI occurs in three clinical settings: primary MI, secondary MI and procedure-related MI.

In this updated approach to MI classification, all MIs fit into one of these three clinical categories, and the new document outlines the diagnostic tests and investigations required for each.

1. Primary MI

Primary MI arises spontaneously due to an acute problem in a coronary artery. It is most commonly caused by a rupture of an atherosclerotic plaque, but there are other causes, such as a tear in the coronary wall (spontaneous coronary artery dissection [SCAD]), spasm or a clot.

2. Secondary MI

Secondary MI arises from an imbalance in oxygen supply and demand in the heart caused by another condition, such as very high or very low blood pressure or a very fast heartbeat.

3. Procedure-Related MI

The third setting—procedure-related MI—is one that occurs within 30 days of a cardiac procedure, such as coronary stenting, or a heart operation, such as coronary artery bypass surgery.

“Clinicians often do not use the previous numerical terminology—e.g. type 2 or type 4c—in patient discussions as it is rather complex. With the new approach, we can now talk with patients about the cause of their MI so that they can understand their condition and recognize why the next steps, such as further tests and treatments, are needed,” said ACC/AHA Chair, Professor Kristin Newby from Duke University Medical Center, Durham, US.

A new artificial intelligence tool could turn a routine heart test into an effective early warning system for serious cardiac emergencies. Doctors have developed an AI tool for analysing an electrocardiogram (ECG). It could study ECG in less than two seconds and identify signs of heart valve disease that may not be visible to the trained human eye.

Developed by researchers at Imperial College London, the AI tool was trained on millions of ECGs and presented at the European Society of Cardiology Congress 2026 in Munich.

In a human trial involving around 67,000 US patients, it was able to detect signs of heart valve disease with up to an astonishing 90% accuracy and heart failure with up to 81% accuracy.

How Can An ECG Reveal A Valve Problem?

A standard ECG records the heart's electrical activity. Traditionally, it has been used to identify heart problems like irregular heart rhythms, but these electrical patterns, according to researchers, can contain signs about the heart's overall structure and function.

The AI looks for patterns across the ECG that may be too complex or subtle for a clinician to recognise visually.

That means the machine isn't simply reading the obvious peaks and dips on an ECG. It is looking for hidden patterns buried within the electrical signal.

Researchers say this could allow routine ECGs, which are already performed millions of times, to flag people who may have an underlying structural heart problem.

Also read: World’s First Live AI-Assisted Brain Surgery Saves Patient’s Sight: How Does The Technology Work?

AI Tool Delivered Accurate Results Within Two Seconds

The results are particularly striking for heart valve disease as the AI tool achieved accuracy of up to 90% in identifying cases.

Heart valve disease occurs when one or more of the heart's valves become narrowed or fail to close properly. This can disrupt the normal flow of blood through the heart.

Some people may have few or no symptoms initially. As the disease progresses, however, it can cause breathlessness, fatigue, chest discomfort, dizziness and swelling, and severe disease can eventually lead to heart failure.

A patient suspected of a heart emergency often requires an ECG, an ultrasound scan that allows doctors to see the heart's chambers and valves. Waiting times for such tests can be long, meaning some patients may remain undiagnosed. The AI could therefore work as a effective tool, identifying people who should be prioritised for echocardiogram.

The AI can analyse an ECG in under two seconds, compared to the much longer process of patients being referred for additional cardiac tests.

Dr Ahmed El-Medany, the British Heart Foundation clinical research fellow who led the Imperial College London analysis, described the tool as a "superhuman AI". The phrase has become shorthand for the project. He also said the next challenge is designing portable AI-based ECG readers.

Dr Sonya Babu-Narayan, consultant cardiologist and BHF clinical director, said she found it exciting to see AI deliver results from an ECG in "what feels like the blink of an eye."

Also read: AI-Designed Viruses Have Been Successfully Tested In Lab But Scientists Are Worried; Here's Why

The technology is being developed as an extra layer of screening. A positive AI result would not mean that someone definitely has heart valve disease. Instead, it could signal that the patient needs a more definitive investigation, such as an echocardiogram.

Heart disease can remain hidden for years before symptoms become obvious. A routine ECG is already a familiar, relatively quick and inexpensive test. If AI can study additional data from that same test, it could help doctors in identifying people who otherwise might not have been investigated and treated further.